Takeda to Present Data at 64th American Society of Hematology (ASH) Annual Meeting, Demonstrating Commitment to Patients with Hematologic Cancers and Other Blood Diseases
− Company to Feature 15 Company-Sponsored and Nine Collaborative Abstracts in Oncology and Hematology − Oral Presentations Include Updated Results from Phase 3 OPTIC Trial of ICLUSIG® (ponatinib) and